Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.96 |
| ▸ | MEN1 | O00255 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.96 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.66 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | GNAO1 | P09471 | 7/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648331 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL10535945 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| N-(Decanoyl)Hexamethyleneimine SCHEMBL5693872 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL5429229 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL472844 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL24073266 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL3752269 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL14879630 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL1407232 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL5435751 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022217147-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | ROSENFELD MARK J (US) | 2022-10-13 | — | — | WO | claimed |
| US-8716279-B2 | Pharmaceutical compositions of clonazepam and method of use thereof | Jazz Pharmaceuticals, Inc. (US) | 2014-05-06 | — | — | US | claimed |
| US-8609651-B2 | Pharmaceutical compositions of benzodiazepines and method of use thereof | Jazz Pharmaceuticals, Inc. (US) | 2013-12-17 | — | — | US | claimed |
| US-20080076761-A1 | Pharmaceutical compositions of clonazepam and method of use thereof | JAZZ PHARMACEUTICALS (US) | 2008-03-27 | — | — | US | claimed |
| US-20080070904-A1 | Pharmaceutical compositions of benzodiazepines and method of use thereof | JAZZ PHARMACEUTICALS (US) | 2008-03-20 | — | — | US | claimed |
| EP-1575617-A1 | USE OF TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING AN ACTIVE AGENT AND PERMEATION-ENHANCING BASE FOR THE MANUFACTURE OF A MEDICAMENT TO TREAT VARIOUS FORMS OF INFLAMMATORY DERMATOSIS | Dermatrends, Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1558228-A1 | TOPICAL ADMINISTRATION OF BASIC ANTIFUNGAL COMPOSITIONS TO TREAT FUNGAL INFECTIONS OF THE NAILS | Dermatrends, Inc. (US) | 2005-08-03 | — | — | EP | claimed |
| EP-1556008-A1 | USE OF BASES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF DIFFERENT FORMS OF INFLAMMATORY DERMATOSIS | Dermatrends, Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| EP-1429791-A4 | METHOD AND TOPICAL FORMULATION FOR TREATING SKIN CONDITIONS ASSOCIATED WITH AGING | DERMATRENDS INC (US) | 2005-01-05 | — | — | EP | claimed |
| US-6821523-B2 | APPLYING BASIC DRUGS TO SKINS FOR PROPHYLAXIS OF HUMAN PAPILLOMAVIRUS INFECTIONS; SKIN DISODERS | DERMATRENDS, INC. | 2004-11-23 | — | — | US | claimed |
| US-6030971-A | INHIBITING BACTERIA FROM ADHERING TO A SUBMERGIBLE SURFACE WITHOUT KILLING THE BACTERIA BY TREATING WITH AN N-HETROCYCLIC AMIDE; ANTIFOULING AGENTS; BOATS; DENISTRY; WATER TREATMENT; IMPLANTS | BUCKMAN LABORATORIES INTERNATIONAL, INC. (US) | 2000-02-29 | — | — | US | claimed |
| EP-0290482-B1 | TRANSDERMAL ABSORPTION DOSAGE UNIT FOR NARCOTIC ANALGESICS AND ANTAGONISTS AND PROCESS FOR ADMINISTRATION | UNIV RUTGERS (US) | 1995-03-08 | — | — | EP | claimed |
| EP-0480996-A1 | BENZOPHENANTHRIDINE ALKALOIDS FOR TOPICAL ACNE TREATMENT | ATRIX LABORATORIES, INC. (US) | 1992-04-22 | — | — | EP | claimed |
| WO-1992000104-A1 | MUCOSAL DELIVERY SYSTEMS FOR TREATMENT OF PERIODONTAL DISEASE | ATRIX LABORATORIES, INC. (US) | 1992-01-09 | — | — | WO | claimed |
| WO-1991000728-A1 | BENZOPHENANTHRIDINE ALKALOIDS FOR TOPICAL ACNE TREATMENT | ATRIX LABORATORIES, INC. (US) | 1991-01-24 | — | — | WO | claimed |
| US-4975271-A | Muscosal delivery systems for treatment of periodontal disease | VIPONT PHARMACEUTICAL, INC. (US) | 1990-12-04 | — | — | US | claimed |
| EP-0290482-A4 | TRANSDERMAL ABSORPTION DOSAGE UNIT FOR NARCOTIC ANALGESICS AND ANTAGONISTS AND PROCESS FOR ADMINISTRATION | — | 1990-11-28 | — | — | EP | claimed |
| US-4806341-A | BACKING LAYER, POLYMER MATRIX DISC WITH DRUG MICRODISPERSED THEREIN | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1989-02-21 | — | — | US | claimed |
| EP-0290482-A1 | TRANSDERMAL ABSORPTION DOSAGE UNIT FOR NARCOTIC ANALGESICS AND ANTAGONISTS AND PROCESS FOR ADMINISTRATION. | UNIV NEW JERSEY (US) | 1988-11-17 | — | — | EP | claimed |
| WO-1988001497-A1 | TRANSDERMAL ABSORPTION DOSAGE UNIT FOR NARCOTIC ANALGESICS AND ANTAGONISTS AND PROCESS FOR ADMINISTRATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1988-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076761-A1 | Pharmaceutical compositions of clonazepam and method of use thereof | GABBR1, GABRA5, GABBR2 | L3MBTL1 4793/4885MEN1 1645/4885KMT2A 1482/4885 |
| US-20080070904-A1 | Pharmaceutical compositions of benzodiazepines and method of use thereof | GABRA5, GABBR1, GABRA6 | L3MBTL1 4806/4885MEN1 1365/4885KMT2A 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.